Furosemide Tablet
NDC Package 67296-2139-3

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings

Package Information

Furosemide tablets is furosemide is used to reduce extra fluid in the body (edema) caused by conditions such as heart failure, liver disease, and kidney disease. This formulation utilizes a tablet delivery system. Marketed by Redpharm Drug, this product is identified by NDC 67296-2139 and is authorized under FDA application ANDA216629.

Identification & Billing

NDC Package Code
67296-2139-3
Package Description
30 TABLET in 1 BOTTLE
Product Code
11-Digit Billing Format
67296213903
RxNorm Crosswalk
RxCUI: 313988 - furosemide 40 MG Oral Tablet

Clinical Specifications

Proprietary Name
Furosemide
Non-Proprietary Name
Furosemide
Substance Name
Furosemide
Dosage Form
Tablet - A solid dosage form containing medicinal substances with or without suitable diluents.
Administration Route
Oral - Administration to or by way of the mouth.
Active Ingredient(s)
Usage Information
Furosemide is used to reduce extra fluid in the body (edema) caused by conditions such as heart failure, liver disease, and kidney disease. This can lessen symptoms such as shortness of breath and swelling in your arms, legs, and abdomen. This drug is also used to treat high blood pressure. Lowering high blood pressure helps prevent strokes, heart attacks, and kidney problems. Furosemide is a "water pill" (diuretic) that causes you to make more urine. This helps your body get rid of extra water and salt.

Regulatory & Marketing

Labeler Name
Redpharm Drug
Product Type
Human Prescription Drug
FDA Application #
ANDA216629
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
11-05-2022
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 67296-2139-3 identifies a specific commercial package of 30 tablet in 1 bottle of Furosemide, a human prescription drug labeled by Redpharm Drug. This tablet is formulated for oral use and contains furosemide as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Redpharm Drug on November 05, 2022. The current certification is valid through December 31, 2026.

What are the primary indications for this medication?

Furosemide is used to reduce extra fluid in the body (edema) caused by conditions such as heart failure, liver disease, and kidney disease. This can lessen symptoms such as shortness of breath and swelling in your arms, legs, and abdomen. This drug is also used to treat high blood pressure. Lowering high blood pressure helps prevent strokes, heart attacks, and kidney problems. Furosemide is a "water pill" (diuretic) that causes you to make more urine. This helps your body get rid of extra water and salt.

How is this Redpharm Drug product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 67296213903. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-4-1)
67296-2139-3
11-Digit CMS (5-4-2)
67296-2139-03

Note: The zero is added to the Package segment to maintain the 5-4-2 structure.